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Background: The present study examines a hypothesis that 
short allergen-derived peptides may shift an Aspergillus fu-
migatus (Afu-) specific TH2 response towards a protective 
TH1. Five overlapping peptides (P1-P5) derived from Asp f1, 
a major allergen/antigen of Afu, were evaluated for prophy-
lactic or therapeutic efficacy in BALB/c mice. Methods: To 
evaluate the prophylactic efficacy, peptides were intranasally 
administered to naïve mice and challenged with Afu-aller-
gens/antigens. For evaluation of therapeutic efficacy, the 
mice were sensitized with Afu-allergens/antigens followed 
by intranasal administration of peptides. The groups were 
compared for the levels of Afu-specific antibodies in sera and 
splenic cytokines evaluated by ELISA. Eosinophil peroxidase 
activity was examined in the lung cell suspensions and lung 
inflammation was assessed by histopathogy. Results: 
Peptides P1-, P2- and P3 decreased Afu-specific IgE (84.5∼ 
98.9%) and IgG antibodies (45.7∼71.6%) in comparison with 
Afu-sensitized mice prophylactically. P1- and P2-treated 
ABPA mice showed decline in Afu-specific IgE (76.4∼88%) 
and IgG antibodies (15∼54%). Increased IgG2a/IgG1 and 
IFN-γ/IL-4 ratios were observed. P1-P3 prophylactically 
and P1 therapeutically decreased IL-5 levels and eosinophil 
peroxidase activity. P1 decreased inflammatory cells’ infiltra-
tion in lung tissue comparable to non-challenged control. 
Conclusion: Asp f1-derived peptide P1, prophylactically and 
therapeutically administered to Balb/c mice, is effective in 
regulating allergic response to allergens/antigens of Afu, 
and may be explored for immunotherapy of allergic aspergil-
losis in humans.
[Immune Network 2009;9(5):179-191]
INTRODUCTION
Allergic bronchopulmonary aspergillosis (ABPA), an allergic 
disorder induced by the fungal pathogen Aspergillus fumiga-
tus (Afu), is characterized by the presence of both type I and 
type III mediated hypersensitivity reactions leading to in-
creased levels of total IgE, specific IgE (Afu-IgE), specific IgG 
(Afu-IgG), blood and pulmonary eosinophilia and upregula-
tion of TH2 pathway with the secretion of IL-4, IL-5, IL-6, 
IL-10 and IL-13 cytokines (1). Increased incidences of ABPA 
in patients of cystic fibrosis (1∼15%), asthma (1∼11%) and 
Aspergillus skin test-positive asthmatic subjects (24∼28%) de-
mand therapeutics that can potentially inhibit pathological 
conditions induced by Afu (2-4). Importance of TH2 cytokine 
biology in propagating inflammatory and pathological re-
sponses in ABPA, suggest that inhibition of TH2 response 
could provide promising therapy against ABPA. It is well es-
tablished that TH1 cells produce cytokines which down-
regulate TH2-induced allergic responses (5). In view of the 
above fact, restoring TH1/TH2 balance by inducing aller-
gen-specific TH1 responses has been found to be a promising 
approach in allergen-specific immunotherapy (SIT). SIT shifts 
the balance of T-cell subsets from TH2- to TH1-type to pro-
duce a long-term, antigen-specific, protective immune re-
sponse with an increase in allergen-specific “blocking” IgG 
and induction of IL-10 secreting T-regulatory or suppressor 
cells (5-11). However, use of allergen-SIT has been cautioned 
in fungal allergic diseases as type III reactions are contributors 
to pathogenesis rather than protection. There are no reports 
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Figure 1. Schematic representation of immunization/treatment schedule followed for prophylactic (A) and therapeutic (B) regimens with Asp f1
peptides P1-P3. i.n.: Intranasally, i.p.: Intraperitoneally, CFA: Complete Freund’s adjuvant, IFA: Incomplete Freund’s adjuvant, 3wcf: three-week 
culture filtrate. 
for allergen-SIT for ABPA but has been reported for asthma 
induced by Cladosporium herbarum and Alternaria alternata 
using purified allergen extracts (12-14). Due to risks involved 
with whole allergen-immunotherapy and benefits of a stand-
ardized manufacture of peptides, attention has been focused 
to immunotherapy with peptides that display reduced IgE- 
binding while retaining T-cell epitopes. It is now plausible 
to attempt the peptide-specific therapy against Afu-induced 
allergic diseases owing to availability of annotated genome 
sequence of Afu and knowledge of characterized immunodo-
minant allergens/antigens. Relevant epitopes in these aller-
gens/antigens have been identified both by prediction algo-
rithms and by experiment (15-22).
  One of the earliest known and characterized allergen/anti-
gen of Afu is Asp f1 with 85% of allergic aspergillosis patients 
showing IgE antibodies to Asp f1 (17,18,23-25). Asp f1 is a 
cytotoxic ribonuclease hindering its use for immunotherapy 
in a native form owing to the possible toxicities and 
IgE-mediated side effects. The present study was undertaken 
to identify promising Asp f1 peptide candidates with capa-
bility of programming the functional activity of Asp f1-specific 
T cells to TH1 type. Studies by various groups suggested 
presence of T cell epitopes in the N-terminal region of Asp 
f1 (1 to 20 amino acid residues) (15,16,26). In an earlier 
study, we evaluated five overlapping peptides (P1-P5) from 
the N-terminal region of Asp f1 for diagnostic relevance (19). 
The same peptides in the present study were predicted for 
their binding to MHC class II alleles of BALB/c mice, and 
evaluated for induced cytokine profile in splenocytes of Afu 
sensitized mice (referred as ABPA mice). Three of these pep-
tides (P1-P3) with significant stimulation index were prophy-
lactically administered to naïve mice, and mice were eval-
Asp f1 Epitopes Protective Against Allergic Aspergillosis
Neelkamal Chaudhary, et al.
181IMMUNE NETWORK http://www.ksimm.or.kr Volume 9 Number 5 October 2009
Table I. Sequences of peptides P1-P5 derived from the N-terminal
region of Asp f1
Peptides Sequence (amino acids)
P1 LNPKTNKWEDK (10∼20)
P2 INQQLNPK (6∼14)
P3 INQQLNPKTNKWEDK (6∼20)
P4 TNKWEDK (14∼20)
P5 LNPKTNKWEDKRY (10∼22)
uated for protection against challenge with Afu allergens/anti-
gens (Fig. 1). Studies were also conducted to investigate 
whether these peptides can therapeutically downregulate es-
tablished TH2 responses in murine model of pulmonary fun-
gal hypersensitivity caused by Afu (which mimic immuno-
logical profile of ABPA).
MATERIALS AND METHODS
In silico prediction of binding affinity of peptides (P1- 
P5) with human and mouse MHC class II molecules
As reported earlier, five overlapping synthetic peptides P1-P5 
from the N-terminal region of Asp f1 were observed to be 
immunodominant (19). Binding affinity (IC50) of these pep-
tides to major human HLA-DR molecules was predicted using 
Support Vector Machine (SVM) method (27). The binding 
with BALB/c MHC class II molecules i.e., I-Ad and I-Ed was 
predicted by the available online server, PREDBALB/C (28).
  For SVM prediction method, the dataset of peptides with 
pre-determined IC50 values with HLA-DR2, DR4, DR5, DR7 
and preponderant alleles like DRB1*1501 (DR2) and DRB1* 
0401 (DR4) were collected from AntiJen database (http:// 
www.jenner.ac.uk/antijen/) and MHCBN database (http:// 
www.imtech.res.in/raghava/mhcbn). This dataset containing 
the peptides and their binding affinity (experimentally de-
termined) was used as an input for the Support Vector 
Machine. SVM parameters were optimized in order to devel-
op the best model and the method was validated using 
five-folds cross validation and leave one out cross validation. 
Correlation between the actual and the predicted affinity val-
ues was calculated and the model at which the correlation 
was the highest (＞0.5) was selected as the SVM model for 
prediction of binding affinities of peptides P1-P5 (27,29). 
Peptides were arbitrarily classified based on their predicted 
IC50 values (high-affinity binders: IC50≤500 nM, medium-af-
finity binders: 500 nM＜IC50≤1,500 nM, low-affinity binders: 
1,500＜IC50≤5,000 nM and non-binders: 5,000＜IC50).
Peptide synthesis and purification
As reported earlier, peptides P1-P5 were synthesized using 
solid phase methodology by standard Fmoc-chemistry and 
purified by reverse-phase HPLC on an analytical CE-18 col-
umn (Applied BioSystems) and characterized by FAB-MS (Fast 
atom bombardment mass spectrophotometry) (Jeol JMS-360) 
(19). Amino acid sequences of the peptides are given in the 
Table I.
Allergens/Antigens
Three-week culture filtrate allergens/antigens (3wcf; protein 
enriched antigenic fraction) of Afu (clinical strain 285, isolated 
from the sputum of an ABPA patient visiting the V. P. Chest 
Institute, Delhi, India) used for the following experiments 
were prepared as described earlier (19,30). The three-week 
culture filtrate was observed to be enriched with diagnosti-
cally relevant allergens including Asp f1 as reported by our 
group and others (18,23). The suitability of the antigen was 
determined by its immunoreactivity with specific IgG and IgE 
antibodies in sera of clinically confirmed ABPA patients by 
ELISA and Western blotting techniques.
Mice
Specific-pathogen-free, 6∼8 week old BALB/c mice were ob-
tained from the National Institute of Nutrition, Hyderabad, 
India. They received Purina chow and acidified water ad 
libitum. Mice were randomized before experiments were 
performed. All procedures involving the handling of mice 
were approved by the institute’s animal ethics committee.
Sensitization of BALB/c mice with 3wcf
A murine model of pulmonary hypersensitivity was prepared 
as described previously (30) and called “ABPA mice” for de-
scriptive convenience.
Lymphoproliferation assay with Asp f1 peptides using 
ABPA mice splenocytes
To assess whether Asp f1 peptides (P1-P5) can stimulate 
Afu-sensitized splenocytes of ABPA mice, in vitro splenocytes 
proliferation was carried out as described previously (19,34).  
Briefly, mice were sacrificed and spleens were removed asep-
tically and placed in an ice-cold PBS. After gentle dis-
sociation, cellular suspensions were cultured in a volume of 
100 μl in 96-well flat-bottom plates at the density of 2×105 
cells. Peptides and 3wcf (final concentration −5 μg/ml) 
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were added into the culture medium and allowed to pro-
liferate in RPMI-1640 medium with 10% (v/v) fetal calf serum 
and 10 μg/ml gentamicin at 37oC and 5% CO2 for 72 hr. 
10 μl of MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide] (Sigma Aldrich, Delhi, India) (5 mg/ml) was 
put in wells, kept for 2∼3 hr; cells were lysed with 0.04 N 
isopropanol-HCl and read at 572 nm.
  Stimulation Index was obtained as: OD572 nm value after 
stimulation with 3wcf or peptides/ OD572 nm value without 
stimulation.
Treatment of naïve and ABPA mice with peptides 
P1-P5
The immunization/treatment schedule followed for prophy-
lactic and therapeutic regimens was optimized considering 
previous studies (31,32). Schematic details of the schedule are 
outlined in Fig. 1. The mice were divided into five groups 
for each regimen (prophylactic and therapeutic), with five 
mice in each group: Non-challenged control mice, P1-treated 
mice, P2-treated mice, P3-treated mice and PBS-treated ABPA 
or Afu challenged mice.
Cytokines in supernatants of spleen cultures before 
and after treatment
Splenocytes of various groups of mice i.e., peptide-treated, 
PBS-treated and control mice after both prophylactic and ther-
apeutic regimens, were allowed to proliferate as described in 
previous section. Peptides and 3wcf (final concentration −5 
μg/ml) were added into the culture medium and allowed 
to proliferate in RPMI-1640 medium (Sigma Aldrich, Delhi, 
India) with 10% (v/v) fetal calf serum (Biological Industries, 
Israel) and 10 μg/ml gentamicin at 37oC and 5% CO2 for 72 
hr. Splenic supernatants obtained were assayed for IL-4, IFN-
γ and IL-5 levels according to the manufacturer’s instructions 
(BD OptEIA kits, BD Pharmingen, CA, USA).
Detection of Afu-specific IgE and IgG antibodies
The Afu-IgG and Afu-IgE levels in the serum were measured 
by ELISA, as reported previously (33). The serum dilutions 
used for IgG and IgE estimation were 1：100 (v/v) and 1：10 
(v/v), respectively. Horseradish peroxidase labeled-goat an-
ti-mouse IgG (Sigma Aldrich, Delhi, India) and IgE (Bethyl 
Labs, TX, USA) conjugates were used at 1：1,000 (v/v) 
dilutions. The optical densities at 490 nm were measured with 
an ELISA reader (SpectraMAX 190, Molecular Devices, CA, 
USA).
IgG isotype specific ELISA
The Afu-IgG1 and IgG2a responses were measured by ELISA 
as described earlier (33). The serum dilution used for IgG1 
and IgG2a estimation was 1：100 (v/v). Horseradish perox-
idase-labeled rat anti-mouse IgG1 and IgG2a (BD pharmin-
gen, CA, USA) antibodies were used at 1：1,000 (v/v) dilu-
tions. The optical densities at 490 nm were measured with 
an ELISA reader (SpectraMAX 190, Molecular Devices, CA, 
USA).
Eosinophil peroxidase (EPO) assay
EPO assay, an indicator of number of eosinophils in activated 
state, was performed as described earlier (30). Briefly, lung 
cell suspension (200 μl/well) was plated in a 96-well tissue 
culture plate and incubated in a humidified CO2 incubator at 
37oC for 48 hours. The medium was aspirated and o-phenyl-
ene diamine (OPD) was added (100 μl of 1 mM solution 
was prepared using sterile PBS containing 0.1% vol/vol Triton 
X-100 and 0.0125% vol/vol H2O2). After 30-minute incubation 
at room temperature, the color reaction was terminated by 
addition of 50 μl of 4 N H2SO4, and the A492 was measured.
Histological examination of the lung sections
Lungs removed from the sacrificed mice were trimmed of ex-
traneous tissue and fixed in 10% (v/v) formaldehyde and stor-
ed at 4oC. The tissue sections, made using a microtome and 
stained with hematoxylin and eosin, were examined at x20.
Statistical analysis
Unless stated otherwise, all data are expressed as mean± 
standard deviation (SD), with five mice per group. Differen-
ces between the mean values of untreated and treated groups 
were analyzed using student’s unpaired t-test available at the 
site http://home.clara.net/sisa/t-test/htm. A p-value ＜0.05 
was considered statistically significant. The data reported was 
pooled from three independent experiments, unless specified 
otherwise.
RESULTS
In silico prediction for binding affinities of Asp f1 
peptides with MHC class II alleles
Peptides P1-P5 were observed to be predicted binders using 
PREDBALB/c server to MHC class II alleles, IAd and IEd (data 
not shown). Peptides P1-P5 exhibited medium binding affin-
ity (500 nM＜IC50≤1,500 nM) to multiple HLA-DR alleles 
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Table II. Predicted binding affinities (IC50) of Asp f1 peptides P1-P5 for dominant HLA-DR moleculesa
Peptides DR2 DR4 DR5 DR7 DRB1*1501 DRB1*0401
P1 473.50 418.52   89.86 1,063.55 1,705.41 1,362.89
P2 459.57 476.21 954.72 1,112.92    718.89    592.10
P3 458.42 389.57 266.06 1,101.09 1,176.40    759.60
P4 443.67 563.45 449.24 1,034.03 1,051.35 1,312.27
P5 503.24 323.90 168.93 1,260.13 1,901.76    814.72
aIC50 values are expressed in nM and have been predicted following Support Vector Machine method as described in Materials and 
methods. Peptides showing the predicted IC50 values inferior to 5,000 nM are considered to be predicted binders in this method
Figure 2. Afu-specific IgE and IgG antibody levels in sera after 10th day of prophylactic (A) and therapeutic (B) treatment with PBS or Asp f1
peptides P1-P3. Each regimen had 5 groups of mice: Non-challenged control, PBS-treated Afu-challenged (prophylactic) or ABPA (therapeutic), 
P1-treated, P2-treated and P3-treated mice. Data represents O.D. at 492 nm and error bars indicate the mean±SD of triplicate determinations 
with five mice per group, *p＜0.05 versus PBS-treated ABPA/Afu challenged mice.
such as HLA-DR2, HLA-DR4, HLA-DR5, HLA-DR7 and also 
with preponderant alleles such as HLADRB1*1501 (DR2) and 
HLADRB1*0401 (DR4) following SVM method except P1 and 
P5 which showed low binding to DRB1*1501 (Table II). With 
alleles DR2, DR4 and DR5, binding affinities were predicted 
to be higher for peptides P1 and P3. Peptides P2 showed 
higher binding to DR2 and DR4 allele while P5 peptide with 
alleles DR4 and DR5. Peptide P1 showed the highest binding 
(IC50∼90 nM) with DR5 allele. Peptide P2 also showed high-
er binding to preponderant alleles DRB1*1501 and DRB1*0401 
when compared to other peptides (Table II).
Asp f1 peptides induce proliferation of ABPA mice 
splenocytes
ABPA mice splenocytes were challenged in vitro with 3wcf 
and peptides P1-P5 (5 μg/ml) and were analyzed for their 
stimulation index. Peptides P1-P3 showed higher stimulation 
index (up to 2.4-fold) indicating that they are Asp f1-derived 
immunodominant epitopic regions recognized by Afu-sensi-
tized splenocytes (data not shown). Peptides, P1-P3 were 
therefore selected for further evaluation in BALB/c mice.
Downregulation of Afu (3wcf)-specific antibody le-
vels by Asp f1 peptides
A significant increase in Afu-IgE and Afu-IgG levels was ob-
served in the groups of ABPA mice before any treatment and  
in Afu-challenged mice immunized for two weeks with 3wcf 
(without any prior treatment), in comparison with those of 
non-challenged control mice immunized with PBS alone (p
＜0.05) (Fig. 2).
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Figure 3. Afu-specific IgG2a and IgG1 antibody levels in sera of PBS-treated and peptide-treated mice groups (P1-P3) after 10th day of  prophylactic
(A) and therapeutic (B) regimen quantitated by indirect ELISA and their respective IgG2a/IgG1 ratios shown below the graph. Each regimen had 
5 groups of mice: Non-challenged control, PBS-treated Afu-challenged (prophylactic) or ABPA (therapeutic), P1-treated, P2-treated and P3-treated
mice. Data represents the mean±SD of triplicate determinations with five mice per group, *p＜0.05 versus PBS-treated Afu challenged 
(prophylactic) or ABPA mice (therapeutic).
  In prophylactic regimen, P1-, P2- and P3-treated naïve mice 
showed significant suppression in Afu-specific IgE levels i.e., 
98.9%, 94% and 84.5%, respectively on day 36 (Fig. 2A, p
＜0.05) in comparison to PBS-treated Afu-challenged mice. 
Similarly, when compared to PBS-treated Afu-challenged 
mice, there was significant suppression in Afu-specific IgG 
levels up to 71.6%, 69.4% and 45.7% in P1-, P2- and 
P3-treated mice, respectively after two-week challenge of Afu 
allergen (Fig. 2A, p＜0.05).
  When compared to PBS-treated ABPA mice, therapeutic ad-
ministration of peptides P1 and P2 for 3 consecutive days re-
sulted in decrease of Afu-IgE levels up to 76.4% and 88%, 
respectively on day 42 of the study (Fig. 2B, p＜0.05). 
However, P3-treated ABPA mice did not show significant de-
crease (∼12.7%) in specific IgE levels (Fig. 2B, p＞0.05).
  In comparison to PBS-treated ABPA mice, P1- and P3- 
treated ABPA mice showed 53.6% and 39.8% decrease in 
Afu-specific IgG levels following therapeutic regimen, re-
spectively (Fig. 2B, p＜0.05). No significant decrease in 
Afu-specific IgG levels was observed in P2-treated ABPA mice 
following therapeutic regimen (Fig. 2B, p＞0.05).
  P1-, P2- and P3-treated naïve mice in a prophylactic regi-
men showed decreased Afu-IgG1 levels while specific IgG2a 
levels remained unaltered after challenged to Afu allergens for 
two weeks (Fig. 3A, p＜0.05). The IgG2a/IgG1 ratios were 
4-fold, 13.4-fold and 9.4-fold higher than PBS-treated Afu- 
challenged mice in P1-, P2- and P3-treated mice, respectively. 
In therapeutic approach, IgG2a/IgG1 ratios were 3-fold and 
7.15-fold higher than PBS-treated ABPA mice in P1- and 
P2-treated ABPA mice, respectively (Fig. 3B, p＜0.05). P3- 
treated ABPA mice showed unaltered levels of specific IgG1 
antibodies with decreased IgG2a levels thus lowering the ratio 
of IgG2a/IgG1 in comparison to PBS-treated ABPA mice (Fig. 
3B, p＞0.05).
Asp f1 peptides induce higher IFN-γ/IL-4 ratios
Ratios of IFN-γ/IL-4 in splenic supernatants of PBS-treated 
Afu-challenged and ABPA mice were found to be 1.98±0.049 
and 1.38±0.069, respectively (Fig. 4A).
  In prophylactic regimen, P1-, P2 and P3-treated naïve mice 
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Figure 4. Levels of IFN-γ and IL-4 cytokines in splenic supernatants of PBS/peptide-treated mice groups (P1-P3) in prophylactic (A) and therapeutic 
regimen (B) quantitated by sandwich ELISA and their respective IFN-γ/IL-4 ratios shown below the graph. Each regimen had 5 groups of mice:
Non-challenged control, PBS-treated Afu-challenged (prophylactic) or ABPA (therapeutic), P1-treated, P2-treated and P3-treated mice. Data 
represents the mean±SD of triplicate determinations with five mice per group, *p＜0.05 versus PBS-treated Afu challenged (prophylactic) or
ABPA mice (therapeutic).
showed 9.74-fold, 12.4-fold and 3.8-fold higher IFN-γ/IL-4 
ratios, when compared to PBS-treated Afu-challenged mice 
(Fig. 4A, p＜0.05). While in a therapeutic regimen, P1-, P2- 
and P3-treated mice showed 9.2-fold, 16.2-fold and 1.9-fold 
higher IFN-γ/IL-4 ratios, when compared to PBS-treated 
ABPA mice (Fig. 4B, p＜0.05).
Asp f1 epitopes reduce lung EPO activity, IL-5 levels 
and lung eosinophilia
In prophylactic regimen, P1-, P2- and P3-treated naïve mice 
showed marked reduction of 25%, 47.2% and 46.2% in lung 
EPO activity, respectively in comparison to PBS-treated 
Afu-challenged mice (Fig. 5A, p＜0.05). Therapeutic ap-
proach, when compared to PBS-treated ABPA mice, P1-trea-
ted ABPA mice showed up to 30.8% decrease in lung eosino-
philic index (EPO) (Fig. 5A, p＜0.05). P2- and P3-treated 
ABPA mice showed unaltered levels of lung EPO index (Fig. 
5A, p＞0.05).
  The reduction in the lung EPO activity correlated well with 
the concomitant reduction in the IL-5 production (Fig. 5B). 
Following the prophylactic regimen, when compared with 
PBS-treated Afu-challenged mice, levels of IL-5 cytokine were 
found to be significantly inhibited in P1 (37.7%), P2 (71.6%) 
and P3 (61.9%)-treated naïve mice (Fig. 5B, p＜0.05). In 
therapeutic regimen, IL-5 levels were significantly decreased 
in P1-treated ABPA mice (up to 26.5%) (Fig. 5B, p＜0.05). 
P2- and P3-treated ABPA mice showed unaltered levels of 
IL-5 cytokine (Fig. 5B, p＞0.05).
  As shown in Fig. 6, histopathological examination of lung 
sections of Afu-challenged and ABPA mice treated with PBS 
alone revealed the extensive chronic inflammatory infiltrates, 
mainly representing lymphocytes and eosinophils (Fig. 6A, 
B). These inflammatory cells were frequently located around 
perivascular and peribronchiolar areas. Mice in the PBS-treat-
ed non-challenged control groups had normal bronchi and 
parenchyma and had no conspicuous cellular infiltrates (Fig. 
6C, D). When examined on 10th day of prophylactic (day 36), 
the infiltration was drastically reduced in P1-treated mice 
comparable to that of PBS-treated control mice (Fig. 6E). 
P2-treated mice also exhibited decrease in lung tissue infiltra-
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Figure 5. Levels of IL-5 cytokine in mice splenic supernatants (A) and Lung EPO (Eosinophil Peroxidase) activity in lung homogenates (B) after
prophylactic and therapeutic treatment with PBS or Asp f1 peptides P1-P3. Data represents the mean±SD of triplicate determinations with five
mice per group, *p＜0.05 versus PBS-treated Afu challenged mice, †p＜0.05 versus PBS-treated ABPA mice.
tion when compared to PBS-treated Afu challenged mice (Fig. 
6F). No marked reduction in tissue infiltration was observed 
in P3-treated mice when compared to PBS-treated Afu-chal-
lenged mice (Fig. 6G). In therapeutic (day 42) regimen, the 
infiltration was markedly reduced in P1 comparable to 
PBS-treated non-challenged control mice (Fig. 6H). P2 and 
P3-treated ABPA mice showed decrease in infiltration when 
compared to PBS treated ABPA mice (Fig. 6I, J).
DISCUSSION
The results demonstrate that peptides derived from the im-
munodominant N-terminal region of Asp f1, a major aller-
gen/antigen of Afu, have immunomodulatory properties lead-
ing to predominant allergen-specific TH1 responses. Several 
studies have reported immunodominant T-cell epitopes de-
rived from house dust mite (Der p1), cat allergens (Fel d1), 
dog allergen (Can f1), and bee venom allergen (PLA-2) which 
inhibited allergen-specific TH2 responses by skewing the im-
mune response towards TH1 (31,32,35-38). Few of these 
studies also emphasized that administration of single im-
munodominant peptide results in inhibition of responses to 
the entire allergen, indicating that not all allergen-derived 
T-cell epitopes have to be present to inhibit allergic responses 
(32,36). In contrast to other IgE-mediated allergies, immuno-
therapeutic interventions against mold allergy have been chal-
lenging due to multiple allergenic components and difficulty 
in standardization of fungal extracts (39-41). Owing to the 
identification of major allergens/antigens of Afu and their im-
munodominant T-cell epitopes, safer peptide based-immuno-
therapy could be more promising approach against Afu -in-
duced allergies (16,19,26).
  Evaluation of Asp f1 peptides (P1-P3) in H2Id BALB/c mice, 
high responders to Afu allergen, indicated capability of these 
peptides in redirecting cytokine profile from TH2 towards 
TH1 in both naïve and ABPA mice. Significant suppression 
and decline in Afu-specific IgE levels observed in prophy-
lactic (in P1-, P2- and P3-treated naïve mice) and therapeutic 
(in P1- and P2-treated ABPA mice) regimen, respectively, 
were associated with increased IFN-γ/IL-4 ratios. Subsequent 
increase in IgG2a/IgG1 ratios observed in the similar groups 
of mice and suppressed Afu-specific IgG levels markedly in 
prophylactic (in P1-, P2- and P3-treated) regimen, indicated 
the shift from predominant TH2 to TH1 type. It has been re-
ported that in the murine system IFN-γ regulates the isotypes 
of antibodies secreted during both in vivo and in vitro humor-
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Figure 6. Histopathological examination of the lung sections stained with hematoxylin and
eosin (H&E) and observed at 20×, from the groups of PBS or Peptide-treated mice in 
prophylactic and therapeutic regimen. (A) PBS-treated Afu-challenged mice (B) PBS-treated 
ABPA mice (C) PBS-treated non-challenged control mice (D) PBS-treated non-challenged 
control mice (E) P1-treated naïve mice (F) P2-treated naïve mice (G) P3-treated naïve mice
(H) P1-treated ABPA mice (I) P2-treated ABPA mice (J) P3-treated ABPA mice. Each micrograph
represents the observations in triplicate (a minimum of 10 fields) made with four lung 
specimens of five mice per group.
al responses, leading to the stimulation of IgG2a secretion 
and in the suppression of secretion of both IgG1 and IgE anti-
bodies (42). Kozutsumi et al studied the effect of Japanese 
cedar pollinosis Cry-consensus peptide (CCP) on Cry j1-spe-
cific TH1/TH2 responses using B10.S as a mice model. 
Corroborating with our results, CCP-treated (subcutaneously) 
mice exhibited increase in Cry j1- specific IgG2a antibodies, 
decreased IgG1 and IgE production, and increased secretion 
of IFN-γ cytokine by splenocytes (43). Similarly, treatment 
of PLA2 (a major bee venom allergen)-sensitized mice with 
intraperitoneal injections of a mixture of three overlapping 
peptides (44∼60 mer) spanning the entire PLA2 molecule 
(100 μg/peptide) induced a sharp drop in PLA2-specific IgE 
antibodies, an increase in specific IgG2a antibodies with T 
cell cytokine secretion shifting from a TH2 to TH1 profile 
(44). In a separate study, it has been reported that pep-
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tides-derived from PLA-2 were able to modulate an estab-
lished TH2 response, indicated by decreased levels of PLA2- 
specific IgE and IgG1 antibodies, and declined IL-4/IFN-γ ra-
tio (31).
  Successful immunotherapy has also been shown to be as-
sociated with reductions in numbers of eosinophils at sites 
of inflammation (45,46). The recruitment and differentiation 
of eosinophil progenitor cells in the bone marrow as well as 
the infiltration and survival of eosinophils at sites of in-
flammation are all regulated by IL-5 (47). Significant reduc-
tion in levels of IL-5 correlated with the reduced eosinophil 
peroxidase (EPO) activity in mice prophylactically treated 
with peptides P1, P2 and P3, and therapeutically with P1. The 
administration of Der p1-derived immunodominant peptide to 
the nasal mucosa of mice protected against airway inflam-
mation with significant reductions in IL-5 levels and eosino-
phil infiltration into the airways following allergen challenge 
(32). However, a decrease in the levels of IL-5 cytokine did 
not result in protection against airway eosinophilia in P3 pep-
tide-treated mice in prophylaxis, suggesting other factors con-
tribute to the reduction in eosinophil numbers as reported 
earlier (48). It was interesting to note that in therapeutic regi-
men P2 peptide induced the decrease in IgE antibodies, 
showed higher ratios of IgG2a/IgG1 antibodies and IFN-γ/ 
IL-4 cytokines than peptides P1 and P3. However, only P1 
treated mice showed reduction in EPO activity, IL-5 and in-
flammatory cells infiltration in lung histological sections com-
parable to non-challenged control. Recently, it is becoming 
clear that immunopathogenesis of fungal infections cannot 
solely be explained in terms of TH1/TH2 balance, and the 
important role of TH17 pathway in fungal infections has been 
reported (49). Importantly, functional antagonism between 
TH17 and Treg has also been described (50). Thus, discrep-
ancy observed between peptide-induced TH1/TH2 cytokine 
profile and resolution of lung inflammation in the present da-
ta suggest that other pathways (possibly TH17or Treg) could 
play significant role in Afu-induced allergies and need to be 
investigated.
  It is important to mention that in previous studies peptide 
P1 induced in vitro histamine release from Afu-sensitized ba-
sophils of ABPA patients higher than peptides P2-P5, al-
though significantly less than the 3wcf (19). Therefore, mech-
anism of protection and induction of TH1 cytokines by pep-
tide P1 both prophylactically and therapeutically in in vivo 
conditions is difficult to explain and requires further studies. 
Akdis and colleagues have reported in their studies that hista-
mine enhances secretion of IFN-γ by allergen-specific TH1 
cells, whereas TH2 cytokines (IL-4, IL-13) were inhibited 
(51,52). Likewise, a recent study by Johansen et al demon-
strated that antihistamine-treated CBA mice exhibit increased 
sensitization against bee-venom allergen extracts leading to 
increased levels of IgE antibodies while decreasing the secre-
tion IgG2a antibodies (53). Further, redirection of the im-
mune response towards TH1 has been demonstrated using 
whole-allergen (with histamine release potential) immuno-
therapy for several IgE-mediated allergies (54).
  Since pulmonary eosinophilia was not inhibited by the 
peptides P2 and P3 in the therapeutic regimen and P3 in pro-
phylactic regimen, it is likely that these peptides may not be 
effective for immunotherapy in the amounts administered and 
doses or routes of the peptide have to be optimized for the 
therapeutic or prophylactic potential.
  Taken together, increased production of protective TH1 an-
tibodies, elevated levels of TH1 cytokines and suppression of 
lung eosinophilia induced by Asp f1 peptides P1 and P2 pro-
phylactically, and P1 therapeutically, establishes the useful-
ness of these peptides in the exploration of peptide-based 
protection against Afu-induced allergies. After establishing the 
protective efficacy of Asp f1 peptides in mice, we evaluated 
whether these results could be extrapolated to humans by 
predicting affinity of the peptides with various MHC class II 
molecules. 
  Peptides P1-P5 were predicted to be promiscuous in the 
present study as shown by their binding (medium binding af-
finity) to HLA-DR alleles such as HLA-DR2, HLA-DR4, HLA- 
DR5, HLA-DR7, and also with preponderant alleles such as 
HLADRB1*1501 (DR2) and HLADRB1*0401 (DR4) following 
SVM method. In Asian-Indian population HLADRB1*1501 
while in Caucasian population both HLADRB1*1501 and 
HLADRB1*0401 cover ∼60% of HLADRB1 allele frequency 
(55,56). Texier et al have identified T-cell epitopic regions 
from the major bee venom allergen, Phospholipase A-2, that 
efficiently bind to the predominant HLA-DRB1 molecules of 
Caucasian populations, suggesting as potential candidates for 
immunotherapy to bee-venom allergy (56). HLA association 
studies have revealed that the predisposition to develop 
ABPA is associated with HLA-DR2 and DR5, and possibly DR4 
or DR7 (15). Therefore, predicted higher affinity of peptide 
epitope P1 than other peptides with HLA-DR5 suggests that 
this peptide may represent as a promising candidate for pep-
tide-based intervention against allergic aspergillosis. However, 
experimental studies are required to confirm the predicted 
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binding affinities to these HLA-alleles.
  To conclude, our data suggests that P1, showing TH1 re-
sponse in both prophylactic and therapeutic regimens in 
Balb/c mice challenged with Afu-allergens/antigens, is the 
most promising candidate and may be explored for the devel-
opment of peptide-based immuno-therapeutics of allergic as-
pergillosis in humans.
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